The Gynecologic Oncology Group's role in developing and evaluating vital research hypotheses for women with cancer of the uterine cervix cannot be understated, as methodical and interpretable conclusions from its many clinical studies have defined, supported and driven the standard of care in several avenues of clinical care. The focus of this presentation was to review for an international audience the principle structure, underlying hypotheses and historical progress in the investigation of chemotherapy options for women identified with recurrent cervix cancer. While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women.